DUBLIN and BOSTON, Medtronic plc today announced study results demonstrating that its quadripolar cardiac resynchronization therapy (CRT) system gives physicians more options to optimize CRT delivery, ...
Results Provide Evidence Supporting Potential Expansion of Indications for CRT in Symptomatic, Permanent Atrial Fibrillation Patient Population MINNEAPOLIS & SAN FRANCISCO--(BUSINESS WIRE)-- Data ...
Medical device major Medtronic plcMDT recently presented an economic analysis of five-year data on cardiac resynchronization therapy (CRT) devices within its Cardiac Rhythm & Heart Failure (CRHF) ...
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in Ambulatory Heart ...
Despite recent advances in best medical therapy for heart failure, patients with New York Heart Association (NYHA) Class III and IV heart failure have high rates of clinical deterioration, ...
NATICK, Mass., Boston Scientific Corporation today welcomed the publication of a sub-analysis of the MADIT-CRT trial data in the current issue of the Journal of American College of Cardiology that ...
A preplanned analysis of the PACIFIC-R confirms findings from the pivotal PACIFIC trial of durvalumab as consolidation therapy in unresectable NSCLC after chemoradiotherapy. Historically, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback